ClinicalTrials.gg

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Program

varegacestat

Also written as “AL102” and “BMS-986115”.

Its studies are mostly in Desmoid Tumors, led by 2 companies.

Drug pageBMS-986115: every studyAll 6 studies of it, academic ones too, with its approvals, label and forms.
Furthest: phase 3, since Apr 23, 20216 company-led studies, 1 open or running

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Immunomeits history only51 open or runningphase 3since Apr 23, 2021Apr 23, 2021none ahead
Bristol-Myers Squibbits history only10 open or runningphase 1since Nov 11, 2013Nov 11, 2013none ahead

How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.

History and studies of every company. Pick one to see its own:

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). An open circle marks the day WHO proposed its name. Dates ahead are the sponsors’ estimates.

  1. Nov 11, 2013First study: phase 1 study in Various Advanced CancerNew to Bristol-Myers SquibbBristol-Myers Squibb · NCT01986218 · 36 enrolled · United States, Australia, Canada
  2. Apr 23, 2021Immunome’s first study: phase 3 study in Desmoid TumorsNew to ImmunomeImmunome · NCT04871282 · 198 enrolled · United States, Australia, Belgium and more
  3. Feb 29, 2024Named varegacestatINNProposed as its International Nonproprietary Name in WHO's List 130 · before, AL102, BMS-986115
  4. Nov 4, 2024Phase 1 study in Healthy VolunteerImmunome · NCT06677996 · 22 enrolled · United States
  5. Jan 24, 2025Phase 1 study in Healthy VolunteerImmunome · NCT06841315 · 35 enrolled · United States
  6. Feb 5, 20252 phase 1 studies in Healthy VolunteerImmunome · NCT06845852, NCT06855264

TargetBeta

Not stated by its company or a source we have read. Most early programs say nothing of it.

Studies

All 6 led by companies developing it, newest first. Each opens its study page.

StudyPhaseStatusLed byPrimary completionSize
NCT06855264Healthy Volunteer · United States1CompletedImmunomeApr 8, 202532
NCT06845852Healthy Volunteer · United States1CompletedImmunomeMar 11, 20256
NCT06841315Healthy Volunteer · United States1CompletedImmunomeNov 5, 202535
NCT06677996Healthy Volunteer · United States1CompletedImmunomeDec 30, 202422
NCT04871282Desmoid Tumors · United States, Australia, Belgium and more3Active, not recruitingImmunomeDec 3, 2025198
NCT01986218Various Advanced Cancer · United States, Australia, Canada1TerminatedBristol-Myers SquibbMar 201636

How it is read

Names in the registry

  • “varegacestat”, 4 entries
  • “AL102”, 1 entry
  • “BMS-986115”, 1 entry

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.